MedPath

A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Phase 2
Conditions
Obesity
Type2 Diabetes
Interventions
Drug: Placebo
Drug: CT-868
Registration Number
NCT05110846
Lead Sponsor
Carmot Therapeutics, Inc.
Brief Summary

A Study to Assess the effect of CT-868 in hemoglobin A1c (HbA1c) in Overweight and Obese Participants with Type 2 Diabetes Mellitus.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
96
Inclusion Criteria
  • Males or Females with T2DM
  • BMI of ≥27 kg/m2, inclusive
  • 18-75 years old, inclusive
  • Stable body weight for 3 months
Read More
Exclusion Criteria
  • Significant medical history
  • Uncontrolled diabetes
  • History of malignancy
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboPlacebo
CT-868 Low DoseCT-868CT-868
CT-868 Maximum Tolerated DoseCT-868CT-868
Primary Outcome Measures
NameTimeMethod
Change in hemoglobin A1c (HbA1c)Baseline up to 12 and 26 weeks
Secondary Outcome Measures
NameTimeMethod
Change in mean body weightBaseline up to 12 and 26 weeks
Fasting plasma glucoseBaseline up to 12 and 26 weeks

Trial Locations

Locations (6)

Carmot Clinical Center MX05

🇲🇽

Mérida, Yucatan, Mexico

Carmot Clinical Center MX03

🇲🇽

Mexico City, Mexico

Carmot Clinical Center MX04

🇲🇽

Guadalajara, Jalisco, Mexico

Carmot Clinical Center MX01

🇲🇽

Monterrey, Nuevo Leon, Mexico

Carmot Clinical Center US01

🇺🇸

Los Angeles, California, United States

Carmot Clinical Center MX02

🇲🇽

Monterrey, Nuevo Leon, Mexico

© Copyright 2025. All Rights Reserved by MedPath